KR20220103977A - 에스트로겐 수용체 조절제의 염 및 형태 - Google Patents

에스트로겐 수용체 조절제의 염 및 형태 Download PDF

Info

Publication number
KR20220103977A
KR20220103977A KR1020227018944A KR20227018944A KR20220103977A KR 20220103977 A KR20220103977 A KR 20220103977A KR 1020227018944 A KR1020227018944 A KR 1020227018944A KR 20227018944 A KR20227018944 A KR 20227018944A KR 20220103977 A KR20220103977 A KR 20220103977A
Authority
KR
South Korea
Prior art keywords
degrees
compound
pharmaceutically acceptable
acceptable salt
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227018944A
Other languages
English (en)
Korean (ko)
Inventor
피터 친후아 후앙
사이 가자난 헥데
케빈 듀언 번커
존 나이트
드보라 헬렌 슬리
Original Assignee
리커리엄 아이피 홀딩스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리커리엄 아이피 홀딩스, 엘엘씨 filed Critical 리커리엄 아이피 홀딩스, 엘엘씨
Publication of KR20220103977A publication Critical patent/KR20220103977A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020227018944A 2019-11-04 2020-11-02 에스트로겐 수용체 조절제의 염 및 형태 Ceased KR20220103977A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930153P 2019-11-04 2019-11-04
US62/930,153 2019-11-04
PCT/US2020/058526 WO2021091819A1 (en) 2019-11-04 2020-11-02 Salts and forms of an estrogen receptor modulator

Publications (1)

Publication Number Publication Date
KR20220103977A true KR20220103977A (ko) 2022-07-25

Family

ID=75849360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227018944A Ceased KR20220103977A (ko) 2019-11-04 2020-11-02 에스트로겐 수용체 조절제의 염 및 형태

Country Status (12)

Country Link
US (1) US20220389006A1 (https=)
EP (1) EP4045507A4 (https=)
JP (1) JP2022553833A (https=)
KR (1) KR20220103977A (https=)
CN (1) CN114945570A (https=)
AU (1) AU2020380211A1 (https=)
BR (1) BR112022008520A2 (https=)
CA (1) CA3159749A1 (https=)
IL (1) IL292680A (https=)
MX (1) MX2022005139A (https=)
TW (1) TW202132294A (https=)
WO (1) WO2021091819A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) * 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
CN114929696A (zh) * 2019-05-24 2022-08-19 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
EP4267578A4 (en) 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
UY35590A (es) * 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
WO2021216671A1 (en) * 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader

Also Published As

Publication number Publication date
TW202132294A (zh) 2021-09-01
EP4045507A4 (en) 2023-11-01
MX2022005139A (es) 2022-06-24
CN114945570A (zh) 2022-08-26
AU2020380211A1 (en) 2022-05-19
CA3159749A1 (en) 2021-05-14
US20220389006A1 (en) 2022-12-08
IL292680A (en) 2022-07-01
BR112022008520A2 (pt) 2022-07-26
JP2022553833A (ja) 2022-12-26
WO2021091819A1 (en) 2021-05-14
EP4045507A1 (en) 2022-08-24

Similar Documents

Publication Publication Date Title
JP7035108B2 (ja) プリドピジンの類似体、それらの製造および使用
TWI896701B (zh) Ｗｅｅ１抑制劑之鹽及形式
US11560369B2 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
JP2022517396A (ja) Ｅｇｆｒ阻害剤の塩、結晶形及びその製造方法
WO2020214921A1 (en) Solid forms of modulators of cftr
HK1248217A1 (zh) 选择性cdk4/6抑制剂的固态形式
KR20220103977A (ko) 에스트로겐 수용체 조절제의 염 및 형태
TW201028142A (en) Heterobicyclic sphingosine 1-phosphate analogs
CN108727347A (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
WO2021150697A1 (en) N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
TWI376373B (en) Crystalline base of a pharmaceutical compound
TW201815793A (zh) 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
US10150739B2 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
WO2023059610A1 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
CA3235907A1 (en) Crystalline forms and processes for the preparation of pyrimidine derivatives useful as modulators of the 5-ht 2a serotonin receptor
WO2023011608A1 (zh) 含三并环类衍生物调节剂、其制备方法和应用
CN114507153A (zh) 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用
CN117957222A (zh) 毒蕈碱受体4拮抗剂及使用方法
JP2022540466A (ja) 非晶質ウムブラリシブモノトシレート
CN116751186B (zh) 一种雌激素受体调节剂的制备及其用途
CN117024397A (zh) 苯丙胺衍生物、其制备方法和应用
CN116655598A (zh) 一种用于降血糖的药物及其制备方法
NZ614787B2 (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601